SIMCERE PHARMA (02096) surged nearly 6%, closing the morning session up 5.83% at HK$13.8, with a turnover of HK$81.83 million. On November 10, the company announced that its self-developed Treg-preferential IL-2 mutant fusion protein (IL-2 mu-Fc) SIM0278 injection, developed in collaboration with Almirall for global clinical studies, has officially initiated a Phase II clinical trial in China. The first patient dosing was completed at Hangzhou First People's Hospital for the treatment of moderate-to-severe atopic dermatitis.

The study is a randomized, double-blind, placebo-controlled multicenter Phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SIM0278 through continuous subcutaneous administration in patients with moderate-to-severe atopic dermatitis.

Additionally, Huatai Securities recently noted in a research report that SIMCERE PHARMA attended the bank’s 2026 Investment Summit on November 5. The company reiterated: 1) Multiple innovative pipelines are entering the commercialization phase, expected to drive revenue growth alongside mature products; 2) The globalization strategy is underway, with early-stage cutting-edge products such as ADCs and autoimmune bispecific antibodies showing global market potential.

The brokerage remains optimistic about the company’s rapid revenue and net profit growth from 2025 to 2027, citing its innovation system being validated through commercialization and overseas expansion. It maintains a "Buy" rating.